Recombinant IL-2 Shows Potential in Atopic Dermatitis : vima

"This is the first study to demonstrate the therapeutic potential of rezpegaldesleukin," said Jonathan Silverberg, MD, PhD, MPH, who presented results of a phase 1b study.

Related Keywords

Washington , United States , Netherlands , Amsterdam , Noord Holland , Berlin , Germany , Reis Matos , Jonathan Silverberg , Eli Lilly , Health Science , Amsterdam University Medical Centers , George Washington University School Of Medicine , European Academy Of Dermatology , Nektar Therapeutics , European Academy , Eczema Area , Severity Index , Body Surface Area , George Washington University School , Medscape Medical News , Peace Corps , Validated Investigator Global Assessment , Atopic Dermatitis , Itch Numeric Rating Scale , Dermatology Life Quality Index , Patient Oriented Eczema Measure , Dermatitis , Biologic Therapy , Interleukin 2 , Sol 2 , Adverse Effects , Side Effects , Clinical Research , Clinical Trials , Linical Studies , Eczema , Interleukins , Quality Of Life , Pol , Ealth Related Quality Of Life , Rqol , Severity Indices ,